|
ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy. |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Elsevier (Inst); Roche/Genentech (Inst) |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Guardant Health (Inst) |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; POINT Biopharma; Roche |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst) |
Expert Testimony - AstraZeneca; Novartis |
|
|
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar |
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis |
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst) |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology (Inst); Pfizer |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/Merck (Inst); Bristol Myers Squibb Foundation (Inst); Janssen-Cilag (Inst) |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Sustained Therapeutics |
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Pfizer; Roche; Sanofi; Tersera |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genova Diagnostics; Janssen; Pfizer; Roche; Sanofi; Tersera |
Research Funding - Astellas Pharma; Bayer; Janssen |
Patents, Royalties, Other Intellectual Property - ST-CP; ST-POP |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
Consulting or Advisory Role - Amunix; AstraZeneca; Daiichi Sankyo Europe GmbH; Illumina; MSD; Pfizer |
Speakers' Bureau - AstraZeneca; Guardant Health; Janssen; Pfizer |
Research Funding - AstraZeneca (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
Other Relationship - Nuage Therapeutics |